Sutro Biopharma Inc (NASDAQ:STRO) price on Friday, June 13, fall -1.50% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.80.
A look at the stock’s price movement, the close in the last trading session was $0.81. Turning to its 52-week performance, $5.17 and $0.52 were the 52-week high and 52-week low respectively. Overall, STRO moved 9.02% over the past month.
Sutro Biopharma Inc’s market cap currently stands at around $67.49 million, with investors looking forward to this quarter’s earnings report slated for in July.
The average forecast suggests down to a -44.17% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 58.84M, representing a -5.16% decline on that reported in the last financial year.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 5 recommend STRO as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
STRO’s current price about -8.73% and -3.80% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 42.75, while 7-day volatility ratio is 1.61% and 3.84% in the 30-day chart. Further, Sutro Biopharma Inc (STRO) has a beta value of 1.71, and an average true range (ATR) of 0.08. Analysts have given the company’s stock an average 52-week price target of $2, forecast between a low of $2 and high of $2. Looking at the price targets, the low is -150.0% off current price level while to achieve the yearly target high, price needs to move -150.0%. Nonetheless, investors will most likely welcome a -150.0% jump to $2 which is the analysts’ median price.
If we refocus on Sutro Biopharma Inc (NASDAQ:STRO), historical trading data shows that trading volumes averaged 1.87 million over the past 3 months. The company’s latest data on shares outstanding shows there are 84.35 million shares.
The 7.60% of Sutro Biopharma Inc’s shares are in the hands of company insiders while institutional holders own 67.16% of the company’s shares. Current price change has pushed the stock -56.57% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the STRO stock continues to rise going into the next quarter.
